Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative study

We determined the optimal timing for initiating androgen receptor signaling inhibitor (ARSI) therapy in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and assessed its impact on oncological outcomes. This retrospective study included 145 nmCRPC patients who received enzalu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Japanese journal of clinical oncology 2024-10
Hauptverfasser: Hara, Shuhei, Urabe, Fumihiko, Tashiro, Kojiro, Goto, Yuma, Iwamoto, Yuya, Ohtsuka, Takashi, Fukuokaya, Wataru, Imai, Yu, Iwatani, Kosuke, Atsuta, Mahito, Mori, Keiichiro, Igarashi, Taro, Aikawa, Koichi, Yanagisawa, Takafumi, Kimura, Shoji, Murakami, Masaya, Tsuzuki, Shunsuke, Yanada, Brendan A, Hata, Kenichi, Furuta, Akira, Yamada, Hiroki, Miki, Jun, Kimura, Takahiro
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We determined the optimal timing for initiating androgen receptor signaling inhibitor (ARSI) therapy in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and assessed its impact on oncological outcomes. This retrospective study included 145 nmCRPC patients who received enzalutamide, apalutamide or darolutamide at the Jikei University Hospital or its affiliated institutions between May 2014 and November 2022. Patients were stratified based on prostate-specific antigen (PSA) doubling time (PSADT) at CRPC diagnosis and PSA levels at ARSI initiation. Oncological outcomes, including progression-free survival (PFS), metastasis-free survival (MFS), cancer-specific survival and overall survival, were assessed using the Kaplan-Meier curve and Cox regression analysis. The median age of the patients was 73 (interquartile range [IQR]: 52-88) years, and the median follow-up duration was 36 (IQR: 2-104) months. The median PSA level at ARSI initiation was 5.4 (IQR: 2.2-48) ng/ml, and 44.8% of patients had a PSADT
ISSN:1465-3621
1465-3621
DOI:10.1093/jjco/hyae146